JCN Newswire Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal Tagged in : early economic lecanemab value with
JCN Newswire Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting Tagged in : alzheimer's clinical disease early eisai's
JCN Newswire Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation Tagged in : clinical early phase study with
ACN Newswire Topelia Australia launches US$25M Series A call for COVID-19 ATT Ziverdox Tagged in : antiviral early therapy topelia triple
JCN Newswire Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer’s Disease Under the Accelerated Approval Pathway Tagged in : early lecanemab living treatment with
ACN Newswire New Horizon Health Announces 2021 Interim Results: Revenue Increases 317% Year-on-year, Gross Profit Margin Climbs to 56.2% Tagged in : cancer early health horizon screening
ACN Newswire DETAK by Brawijaya University Researchers detects Heart Disease Early and Accurately Tagged in : detection disease early heart with
